Cytoflavin
Phase 3Small molecule
Cytoflavin is one of 72 small molecule programs targeting Stroke. It is currently in Phase 3.
3
Indications
6
Total Trials
1
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Cytoflavin
PPOLYSAN Scientific & Technological Pharmaceutical Company
Phase 3
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Stroke2 trials
Ischemic stroke1 trial
Efficacy and Safety1 trial
Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT03849664·200 enrolled
Head Trauma1 trial
International Trial of Efficacy of Cytoflavin in Head Trauma
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT04631484·166 enrolled
Diabetic Polyneuropathy1 trial
Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT04649203·216 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cytoflavin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details